Biotech investor, operator & BD | Drug development | EIR @MSKCancerCenter | 🦋 https://xitter.cf/t.co/TRDbxTeeqJ
New York, NY
Joined June 2011
- Tweets3.3K
- Following2.2K
- Followers848
- Likes3K
Long awaited results from INTerpath-001, the first Phase 3 trial to demonstrate efficacy of a personalized mRNA therapy!
Intismeran met key endpoints in melanoma $MRNA $MRK
A pivotal advance in personalized medicine! #ESMO26
merck.com/news/merck-and-mod…
Great piece on Tolerance Bio. It’s fantastic to see what the team has achieved in less than two years since we led the founding round
biobuzz.io/news/tolerance-bi…
Ruben Sebastian retweeted
Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma. fiercebiotech.com/biotech/to…
Tolerance Bio expands its #thymus focused pipeline, now adding a clinical-stage anti-IL-33 antibody
This is the second clinical program with the recently licensed long-acting IL-7. Tolerance further broadens its leading pipeline targeting thymic biology
businesswire.com/news/home/2…
Great news from Minoryx! Major milestone for the cALD patient community.
NEZGLYAL® (leriglitazone), developed by Minoryx, is now approved in Europe as the first pharmacological treatment for cALD, a rare neurodegenerative disease.
minoryx.com/media/european-c…
Historic approval!
$RVMD
fda.gov/news-events/press-an…
Ruben Sebastian retweeted
I have to say, when Merck called me last night with the mRNA cancer vaccine news (embargoed, of course), I literally yelped in reaction.
Consider this: Between this spring's Revolution Medicines success with a KRAS-targeted drug and now Merck and Moderna's success with an mRNA neoantigen vaccine, 2026 will go down as one of the most consequential years in cancer treatment, ever.
Incredible.
Proud of former portfolio company Minoryx Therapeutics!
Leriglitazone (NEZGLYAL) receives a positive opinion from EMA for the treatment of cALD. Impressive achievement by a Barcelona born biotech with massive implications for the cALD patient community!
minoryx.com/media/leriglitaz…
Confirmed: Abbvie to acquire Apogee for $10.9 billion, strengthening its immunology franchise with $APGE portfolio of long-acting antibodies
Great day to be a holder of $APGE and $ABBV!
news.abbvie.com/2026-06-22-A…
Abbvie reportedly in advanced negotiations to acquire Apogee $APGE!
Scoop by @mroliverbarnes @FT
ft.com/content/cb5e94aa-1687…
Servier to acquire Edgewise muscular #dystrophy business for up to $2.65 billion
Includes sevasemten, an oral first-in-class fast skeletal myosin inhibitor. Currently in a pivotal cohort in Becker, and in Ph2 in #Duchenne
Proud holder $EWTX!
prnewswire.com/news-releases…
Personalized neoantigen mRNA vaccine (intismeran autogene) 5 year follow-up in metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
#ASCO26 $MRK $MRNA
merck.com/news/moderna-and-m…
This is why we do what we do! Foundational research leads to novel medicines for the benefit of our patients. Congrats $RVMD, Brian Wolpin, @EileenMOReilly and everyone involved!
Today is a day to celebrate science, drug development and biotech! #ASCO26
Lilly to acquire Ajax for up to $2.3B. Its lead program (AJ1-11095) is a once-daily oral first-in-class type II #JAK2 inhibitor
Great story for the NYC #biotech ecosystem! Kudos to the founding scientists from @MSKCancerCenter, @nyuniversity & Schrodinger
prnewswire.com/news-releases…
Great news from Oruka $ORKA! ORKA-001, half-life extended IL-23p19 mAb, achieved 63.5% PASI 100 at week 16 in a Phase 2a #psoriasis trial
ir.orukatx.com/news-releases…
We’re witnessing impressive advances in pancreatic cancer! A pancreatic cancer mRNA vaccine shows a very strong and durable immune response in a Phase 1 trial. New 6-year data are being presented today at #AACR2026 @MSKCancerCenter
nbcnews.com/health/cancer/pa…
Lilly to acquire Kelonia to advance in vivo CAR-T cell therapies for $3.25 billion upfront and up to $7 billion
Kelonia's lead program is an i.v. gene therapy that generates anti-BCMA CAR-T cells in vivo and is currently in Ph1 for r/r multiple myeloma
investor.lilly.com/news-rele…
